Analysis: U.S. move to negotiate drug prices a rare defeat for Big Pharma - Reuters
Big Pharma spent more than any other industry to lobby Congress and federal agencies this year, a Reuters analysis shows, but is still on course for a major defeat by failing to stop a bill that allows the government to negotiate prices on select drugs.